Flexion Therapeutics has announced that Kerry Wentworth, Chief Regulatory Officer, has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors.
“It is a pleasure to welcome Kerry to our Board of Directors,” said Robert K. Coughlin, President and CEO of MassBio. “Kerry is an experienced and highly-regarded leader in the life sciences industry, and we are confident her insights and business acumen will be invaluable to our member organizations and the individuals we serve.”
MassBio is a not-for-profit organization representing more than 1,100 life sciences companies, academic institutions, disease foundations, and other organizations involved in healthcare. The MassBio Board of Directors comprises a select group of leaders committed to guiding the organization in its mission to grow Massachusetts' life sciences industry, add value to the healthcare system, and improve patient lives.
“I am honored to join the MassBio Board, and I look forward to collaborating with my esteemed colleagues as we work to advance healthcare policy, promote education and, most importantly, improve the lives of patients,” said Ms. Wentworth.
Ms. Wentworth brings to the MassBio Board of Directors deep expertise in both domestic and international Regulatory Affairs that spans early and late development across multiple therapeutic areas. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for nearly 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc., where she was responsible for advancing their lead program through Phase 3 development and into the registration phase with FDA and EMA. Ms. Wentworth also held positions of increasing responsibility within Regulatory Affairs at Genzyme.
